<DOC>
	<DOCNO>NCT00079950</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Pegamotecan ( Peg-Camptothecin ) patient Advanced Metastatic Soft Tissue sarcoma .</brief_summary>
	<brief_title>Efficacy Safety Evaluation Pegamotecan ( PEG-camptothecin ) Advanced Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis soft tissue sarcoma measurable disease . Target tumor outside prior radiation field ( ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Adequate hematologic profile , determine hemoglobin , platelet , neutrophil count . Adequate renal function Adequate liver function No history hemorrhagic cystitis evidence microscopic hematuria Capable understanding protocol requirement risk provide write informed consent . Either 0 1 prior chemotherapy regimen Subject diagnosis gastrointestinal stromal tumor . Concurrent serious medical illness unrelated tumor within past 6 month . Known chronic infectious disease , AIDS hepatitis . Positive screening pregnancy test breastfeeding . A female male subject reproductive capacity unwilling use method appropriate prevent pregnancy course study . Receiving concurrent chemotherapy , radiotherapy , surgery , receive wide field radiation within previous 4 week . History another active malignancy ( except nonmelanoma skin cancer carcinoma situ cervix ) , unless complete remission therapy disease last 2 year . Known clinically suspect brain metastasis . Received one prior treatment regimen ( exclude adjuvant neoadjuvant therapy ) soft tissue sarcoma . Received investigational drug within last 30 day . Not fully recover prior surgery ( least 4 week recovery period major surgery ) , reversible side effect relate administration cytotoxic chemotherapy radiation therapy . Received prior camptothecin analog ( e.g. , topotecan , irinotecan ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>soft</keyword>
	<keyword>sarcoma</keyword>
	<keyword>metastatic</keyword>
</DOC>